PEP-010
Recurrent and/or metastatic solid tumors (including pancreatic cancer)
Phase 1a/bActive
Key Facts
Indication
Recurrent and/or metastatic solid tumors (including pancreatic cancer)
Phase
Phase 1a/b
Status
Active
Company
About PEP-Therapy
PEP-Therapy is a private, Paris-based biotech leveraging a novel intracellular drug delivery platform to develop targeted peptide therapies for cancer. The company's lead asset, PEP-010, is in Phase Ia/b trials for recurrent/metastatic solid tumors and recently received FDA Orphan Drug Designation for pancreatic cancer. Backed by international venture capital and strategic partnerships with premier cancer centers, PEP-Therapy aims to address undruggable intracellular targets and improve therapeutic performance.
View full company profile